EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Case Report: Olmesartan-Induced Enteropathy Mimicking Amyloidosis in the Setting of New Multiple Myeloma Diagnosis

Mohamad Mahdi Osman, Moises Salgado-de la Mora, Rishaan Sharma, Abdelwahab Ahmed, Sima Fansa, Talal Massad, Hussam Kawas, Mohamed El Hag, Vitaliy Rotenberg

Case Reports in Gastroenterology · 12.05.2026 · 20 (1) · 210-215

DOI: 10.1159/000552526 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Gastroenterology, online erschienen am 12.05.2026. Verfasst von Mohamad Mahdi Osman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Olmesartan-induced enteropathy is an uncommon but important cause of severe chronic diarrhea and weight loss that can mimic celiac disease and infiltrative gastrointestinal disorders. Case Presentation: We report a 71-year-old man on long-term olmesartan who presented with months of diarrhea, nausea/vomiting, profound weakness, and ∼100 pounds of unintentional weight loss. Esophagogastroduodenoscopy demonstrated duodenal villous blunting with lamina propria lymphoplasmacytic inflammation and rare periodic acid-Schiff-positive macrophages. An empiric 3-week gluten-free diet trial was ineffective. Celiac serologies, infectious stool studies, and HIV testing were negative. Laboratory evaluation revealed anemia, elevated creatinine, hypercalcemia, and a gamma gap; serum and urine protein electrophoresis showed an M-protein, and bone marrow biopsy confirmed multiple myeloma. Repeat duodenal biopsies again showed villous blunting, while Congo red staining was negative, arguing against gastrointestinal amyloidosis. Olmesartan-induced enteropathy was favored; olmesartan was discontinued and budesonide was started. Within 1 month, gastrointestinal symptoms resolved and the patient gained 20 pounds.

Conclusion

Recognition of this drug effect is critical, particularly when concurrent hematologic disease raises concern for infiltrative etiologies.

Schlagwörter

Stichwörter der Autor:innen

AmyloidosisCeliac diseaseDrug-induced enteropathyMultiple myelomaSmall intestine

Autor:innen und Institutionen

  • Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Department of Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Department of Gastroenterology, Weill Cornell, New York, NY, USA.
  • Department of Pathology, Cleveland Clinic Foundation, Cleveland, OH, USA.

Zitieren

APA

Osman, M. M., Salgado-de la Mora, M., Sharma, R., Ahmed, A., Fansa, S., Massad, T., Kawas, H., El Hag, M., & Rotenberg, V. (2026). Case Report: Olmesartan-Induced Enteropathy Mimicking Amyloidosis in the Setting of New Multiple Myeloma Diagnosis. Case Reports in Gastroenterology, 20(1), 210-215. https://doi.org/10.1159/000552526

Vancouver

Osman MM, Salgado-de la Mora M, Sharma R, Ahmed A, Fansa S, Massad T, et al. Case Report: Olmesartan-Induced Enteropathy Mimicking Amyloidosis in the Setting of New Multiple Myeloma Diagnosis. Case Reports in Gastroenterology. 2026;20(1):210-215. doi:10.1159/000552526

BibTeX
@article{Osman2026,
  author = {Osman, Mohamad Mahdi and Salgado-de la Mora, Moises and Sharma, Rishaan and Ahmed, Abdelwahab and Fansa, Sima and Massad, Talal and Kawas, Hussam and El Hag, Mohamed and Rotenberg, Vitaliy},
  title = {Case Report: Olmesartan-Induced Enteropathy Mimicking Amyloidosis in the Setting of New Multiple Myeloma Diagnosis},
  journal = {Case Reports in Gastroenterology},
  year = {2026},
  volume = {20},
  number = {1},
  pages = {210--215},
  doi = {10.1159/000552526}
}
Kostenlos starten →